Filtered library · Conviction
MEDIUM conviction · 298 dossiers
Every dossier the model currently rates MEDIUM conviction — 298 names, with thesis, invalidation trigger, archetype and catalyst.
All 298 are dated research with a published kill line — the level named in advance that would prove the call wrong.
All dossiers AMD Advanced Micro Devices, Inc. fresh MEDIUM Advanced Micro Devices’ Helios story depends on OpenAI bringing the platform online in the fourth quarter of 2026. Confirmed operation would settle the deployment case; a weekly close below $456 or activation postponed beyond that quarter… IRDM Iridium Communications Inc fresh MEDIUM Iridium Communications’ merger-discount thesis now has completed financing behind it; acquisition completion before a weekly close below $43.50 settles the case. Rocket Lab’s 2026-09-15 funding announcement advances the transaction, while… MRCY Mercury Systems Inc fresh MEDIUM Defense-electronics turnaround still re-rating on record bookings and a promised FCF turn, but the stock has given back ~20% from its $128.45 ATH and now chops near the analyst median (~$103) into a binary ~Aug 10-18 Q4/full-year print.… MU Micron Technology, Inc. fresh MEDIUM Micron Technology's contracted memory revenue supports an earnings-durability thesis tested on 2026-09-30 against June's $50.0 billion ±$1.0 billion revenue guidance and an 86% adjusted gross-margin benchmark. A weekly close below $958… NTAP NetApp, Inc. fresh MEDIUM NetApp's AI storage recovery requires delivery of September guidance before a weekly close below $164 breaks the thesis. Fiscal-Q2 revenue of at least $2.025 billion and non-GAAP gross margin of at least 67.0%, with the annual revenue… OKTA Okta, Inc. fresh MEDIUM Identity-security re-rating in its second, sell-side-led leg; the upgrade wave is still building nearly two months post-print — Wells Fargo lifted its target to $150 from $100 on 2026-07-20, collapsing the low-end dispersion. Cyber theme… OSCR Oscar Health, Inc. fresh MEDIUM Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026… RXO RXO, Inc. fresh MEDIUM Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground — bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to… SIMO Silicon Motion Technology Corporation fresh MEDIUM Silicon Motion's enterprise-storage expansion needs third-quarter 2026 revenue of at least $519 million to validate the recovery before a weekly close below $230 breaks it. September 15 supply and customer-ramp commentary supports the… SNDK Sandisk Corporation fresh MEDIUM Sandisk’s contracted-revenue story has regained its post-Investor Day price level, leaving fiscal Q1 2027 delivery as the unresolved test. Revenue of at least $10.3 billion and non-GAAP gross margin of at least 83% would complete the case… TXG 10x Genomics, Inc. fresh MEDIUM 10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a… XMTR Xometry, Inc. fresh MEDIUM Xometry's AI manufacturing thesis requires enterprise adoption to deliver its August 4 guidance before a weekly close below $85. Third-quarter revenue of at least $234 million and adjusted EBITDA of at least $16 million, with the 33–34%… AAMI Acadian Asset Management Inc. MEDIUM Acadian Asset Management’s repricing depends on client inflows sustaining higher fees and margins. Positive third-quarter flows, management fees of at least $176.5 million and an economic net income operating margin of at least 40.3% would… ABCL AbCellera Biologics Inc. fresh MEDIUM AbCellera's monthly hot-flash antibody thesis requires the 2026-10-01 presentation to preserve the Phase 2 efficacy case and a subsequent weekly close above $12.73; a weekly close below $9.75 invalidates it. ABSI Absci Corporation fresh MEDIUM Absci Corporation’s valuation rests on ABS-201 delivering human hair-growth efficacy in the guided second half of 2026. Separation from placebo would validate the case; a weekly close below $7.50, absent efficacy or a missed readout window… ADPT Adaptive Biotechnologies Corporation MEDIUM clonoSEQ MRD pure-play inflecting to self-funding growth (MRD rev +53% YoY, profitability turning); June 15 Immune Medicine separation adds a value-unlock leg. But the tape just broke to fresh 52-wk highs (~$22.92) above the $20–22… AEHR Aehr Test Systems MEDIUM Aehr Test Systems’ AI burn-in orders support a revenue-ramp thesis; the next results must preserve fiscal 2027 guidance of $130–150 million. The recovery case requires a weekly close above Lake Street’s $110 target before a weekly close… AGCO AGCO Corporation MEDIUM AGCO Corporation's valuation reflects a 2027 farm-equipment recovery that remains unconfirmed by reported demand. A weekly close above the $139.71 market high recorded as of 2026-09-04 and Q3 results meeting July guidance would confirm the… AGM Federal Agricultural Mortgage Corporation fresh MEDIUM Federal Agricultural Mortgage Corporation's infrastructure lending supports an earnings-led re-rating. The next quarterly report tests whether spread income grows with volume; a weekly close above $240.02 fulfills the price case, while a… ALVO Alvotech MEDIUM Alvotech's recovery prices in Q4 2026 FDA approvals after the Reykjavik inspection closure announced on 2026-07-29. AVT05 and AVT06 approvals within that window would confirm the regulatory-repair case; another manufacturing-related… APPN Appian Corporation fresh MEDIUM Appian’s AI orchestration re-rating needs Q3 revenue of at least $214 million and cloud subscriptions of at least $133 million to confirm management’s August guidance. A weekly close below $34 or a miss against either revenue floor… AQST Aquestive Therapeutics, Inc. MEDIUM Aquestive Therapeutics' recovery thesis rests on an Anaphylm resubmission by 2026-09-30, following its August usability results. A filing announcement before a weekly close below $4.47 would satisfy the near-term case; missing the deadline… ASST Strive, Inc. MEDIUM Strive, Inc.'s bitcoin-treasury premium thesis depends on increasing bitcoin per diluted common share. A company-reported year-to-date Bitcoin Yield above the 40.8% reading dated 2026-08-28 would confirm the case before a weekly close… ASTH Astrana Health Inc. MEDIUM Astrana Health’s full-risk care story depends on meeting Q3 revenue and profit guidance while preserving its raised annual profit outlook. That operational result must arrive before a weekly close below $34 invalidates the recovery thesis. ATRC AtriCure, Inc. fresh MEDIUM AtriCure’s profitability and clinical-expansion story now has to sustain its re-rating after September 21 index inclusion. A weekly close at or above Needham’s $64 target would complete the price case; a weekly close below $47 would… AVAH Aveanna Healthcare Holdings Inc. fresh MEDIUM Aveanna Healthcare’s earnings recovery supports further revaluation if its next report raises annual adjusted EBITDA guidance above the greater-than-$365 million outlook set on 2026-08-13. A weekly close below $11.75 or an unchanged or… BBNX Beta Bionics, Inc. fresh MEDIUM Beta Bionics’ new case is Mint commercialization after the September revenue cut broke the iLet growth thesis. Full U.S. launch within management’s Q1 2027 window would confirm the case; a weekly close below $17.25 would invalidate it. BULL Webull Corporation MEDIUM June dormant-to-leader flip is confirming: the ~$7.52 breakout resolved up on the 2026-07-21 surge, Rosenblatt lifted its target to $13 (2026-07-16), and June ops printed 28.2M users / $800M net deposits. Theme accelerating; read is a… BWLP BW LPG Limited fresh MEDIUM BW LPG Limited’s contracted freight earnings support dividend continuation; its 2026-11-24 report must show Q3 realised shipping TCE above Q2’s $74,000 per day and a dividend of at least $0.95 per share. A weekly close below $22.00… CDNA CareDx, Inc. MEDIUM CareDx’s reimbursement repricing depends on its next quarterly report sustaining the $490–500 million revenue outlook issued on 2026-07-30. Canaccord’s 2026-09-02 initiation renewed attention, but a weekly close below $44 would invalidate… CLDT Chatham Lodging Trust fresh MEDIUM Chatham Lodging Trust’s raised earnings outlook depends on sustained Silicon Valley hotel demand. The case resolves if third-quarter results preserve the August 4 guidance and regional outperformance before a weekly close below $12.00. CLF Cleveland-Cliffs Inc. fresh MEDIUM Cleveland-Cliffs’ tariff-supported cash-flow recovery needs another positive quarter and a weekly close above $12.50. A weekly close below $11.62 would invalidate the recovery, while unresolved labor terms remain the nearest operating… CLMT Calumet, Inc. fresh MEDIUM Calumet’s lower-cost aviation-fuel expansion supports its re-rating if year-end 2026 production exceeds an annual 80 million gallons within the disclosed $137 million remaining-capital plan. The final loan draw reported on 2026-09-14… CMBT CMB.TECH NV fresh MEDIUM CMB.TECH's vessel-disposal and cash-return story supports further upside if the proposed October distribution is delivered. The case requires payment of $0.64 per share and a weekly close above $20.41 by 2026-10-31, before a weekly close… CMPS COMPASS Pathways Plc MEDIUM Compass Pathways’ September 9 COMP360 durability update renews the regulatory revaluation case ahead of its company-guided Q4 2026 submission. A weekly close above the September 11 series’ $15.17 52-week high would confirm the price… CNH CNH INDUSTRIAL N.V. MEDIUM CNH Industrial's farm-equipment recovery is being priced ahead of earnings after September's analyst upgrades. The next quarterly report tests margin recovery, while a weekly close below $12.50 invalidates the re-rating leg. COIN Coinbase Global, Inc. fresh MEDIUM Coinbase’s recovery now rests on agency-led crypto market access after the Senate setback. Confirmation requires a weekly close above the historical $196.07 reference and third-quarter subscription-and-services revenue within the published… CRDL Cardiol Therapeutics Inc. Class A MEDIUM Cardiol Therapeutics’ enrollment-led re-rating requires MAVERIC completion by 2026-09-30 and a weekly close above $2.29 before a weekly close below $1.75. The 2026-09-10 preliminary shelf introduces financing capacity, but the announcement… CRM Salesforce, Inc. fresh MEDIUM De-rated Dow software incumbent on two dated legs: the $1.6B VA agentic ELA (2026-07-24) and Reuters' 2026-08-13 report of Silver Lake–Workday take-private talks, which put a private-market floor under mega-cap SaaS. Six target revisions… CRSR Corsair Gaming, Inc. MEDIUM Corsair Gaming's margin-recovery story is approaching its $14.35 annual high; a weekly close above that level would confirm the recovery leg. A weekly close below the market's $10.93 August anchor would invalidate it, while the next… CRWD CrowdStrike Holdings, Inc. fresh MEDIUM Fal.Con (2026-08-31 to 09-03) delivered real product — Falcon Guardian, Falcon IQ, GPT-5.6 Cyber in Falcon, Anthropic marketplace distribution — and nine broker actions through 2026-09-04 including Truist $300, yet CRWD closed $213.10 on… CRWV CoreWeave, Inc. fresh MEDIUM Post-print repricing is holding but fading: the 2026-08-12 gap to $107.73 is unfilled after closes of $106.29 and $105.26, RSI 71.1. Q2 printed $128M adjusted operating income against a $30–90M guide, and the $2.6B facility closed… CVI CVR ENERGY, INC. MEDIUM CVR Energy’s refining thesis is that Hormuz disruption lifts reported margins above second-quarter 2026’s $9.94 per throughput barrel. Third-quarter results test that inference; a weekly close below $39 invalidates the price structure. CXW CoreCivic, Inc. MEDIUM CoreCivic's facility sales support a real-estate monetization thesis; another completed sale by third-quarter results must confirm its next leg while operating contracts remain intact. A weekly close below $31 invalidates the price thesis. CYRX CryoPort, Inc. MEDIUM Q2 (2026-08-06) split the read: revenue $49.0M beat $48.21M and FY26 guide affirmed at $192–196M with adjusted EBITDA crossing to +$0.4M, but commercial CGT growth halved to +9% YoY from +26%. The narrative leg is now the profitability… DCTH Delcath Systems, Inc. fresh MEDIUM Delcath Systems’ self-funded liver-treatment expansion must sustain its raised revenue outlook. Confirmation requires maintained $104–108 million guidance at the next quarterly report and a weekly close above $17.36 before a weekly close… DINO HF Sinclair Corporation MEDIUM HF Sinclair’s refining-margin and separation story now has fresh UBS support. The case requires the next quarterly report to sustain second-quarter adjusted refinery gross margin of $25.95 per produced barrel sold on comparable throughput,… DK Delek US Holdings, Inc. MEDIUM Delek US's refining recovery supports the August breakout, but September's distillate build weakens the scarcity leg. Q3 throughput and expense delivery must confirm the earnings case before a weekly close below $64 invalidates the… DPRO Draganfly Inc. MEDIUM Draganfly's policy-led drone re-rating now has a Canadian defence contract behind it, announced on 2026-09-11. A weekly close above the historical $6.23 reference would confirm price recovery; a weekly close below $4.70 would invalidate… EGO Eldorado Gold Corporation MEDIUM Eldorado Gold’s Skouries expansion thesis now hinges on fourth-quarter 2026 commercial production after first concentrate on September 8. Delivery before a weekly close below $40 would validate the case; a delay into 2027 would contradict… ETON Eton Pharmaceuticals, Inc. MEDIUM Eton Pharmaceuticals’ re-rating rests on repeatable rare-disease product revenue. Confirmation requires third-quarter product sales to match or exceed the $37.568 million reported on 2026-08-13 and annual revenue guidance above $145… EWTX Edgewise Therapeutics, Inc. MEDIUM Edgewise Therapeutics’ cardiovascular re-rating rests on EDG-7500 entering Phase 3 in Q4 2026 and price expanding above its reference high. Initiation by 2026-12-31 and a weekly close above $48.35 would confirm the case; a weekly close… FA First Advantage Corporation MEDIUM Aug 6 flipped the frame: Q2 revenue $448.8M/+14.9% vs $415.0M consensus, adj EPS $0.35 vs $0.28, and the first FY guide raise of the cycle ($1.67–1.71B). Needham upgraded to Buy/$28, RBC to $24 — targets moved above spot for the first… FBIZ First Business Financial Services, Inc. fresh MEDIUM First Business Financial Services’ earnings re-rating depends on Q3 sustaining its 3.78% margin and exceeding $19.8 million in pre-tax pre-provision earnings. The thesis fails on a weekly close below $68 or deterioration below those Q2… FIGS FIGS, Inc. MEDIUM The post-print shelf resolved upward: the 2026-08-28 close of $15.42 sits 8.1% above the 2026-08-07 mark of $14.26 and 9.9% under the $17.12 52-week high, with no company-dated news since the 2026-08-07 target revisions. The re-rating off… FRNM Freenome, Inc. MEDIUM Freenome's approved blood-test story depends on Abbott launching SimpleScreen CRC and demonstrating reimbursed testing. Carelon's 2026-11-15 guideline strengthens the pathway; a weekly close below $14 or no US launch by 2026-12-31… FROG JFrog Ltd. fresh MEDIUM Software-supply-chain-security plus AI-agent "trust layer" narrative keeps re-rating: the analyst cluster now leads price above $100 (UBS Buy $110 Jul 2, Truist Buy $105 Jul 9), confirming the continuation tell flagged in June.… FSM Fortuna Mining Corp. MEDIUM Fortuna Mining’s gold-supported cash generation funds its mine-growth story, but the September 11 retreat weakens the recovery case. A weekly close above $13.66 before a weekly close below $11.00 would confirm the equity thesis. FTK Flotek Industries, Inc. fresh MEDIUM Legacy oilfield chemistry re-rating into a power/measurement business: Data Analytics hit 51% of gross profit in Q2 2026, the 2026-08-03 PREPA award adds ~$400M of 10-year expected backlog, and the 2026-08-04 guide went to $340–350M from… FTNT Fortinet, Inc. fresh MEDIUM Q2 (2026-07-29) resolved up — revenue $2.047B vs ~$1.89B, product +52% YoY, FY26 guide raised to $8.020–8.180B — but price has gone nowhere since: $161.95 on 07-31, $160.01 on 08-14, still 4.9% under the $168.29 high. The 44-analyst mean… GEO The GEO Group, Inc. MEDIUM The GEO Group’s detention-contract story depends on year-end 2026 activation, with normalized earnings expected in early 2027. A weekly close above $32.77 would confirm the price leg; a weekly close below $28 or a disclosed activation… GHRS GH Research PLC MEDIUM Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next… GTLB GitLab Inc. fresh MEDIUM GitLab's consumption-pricing story needs coding-agent usage to lift revenue above its September guidance. Fiscal Q3 revenue above $283 million and a paid-consumption run-rate above September's $40 million reference would confirm the case… HAE Haemonetics Corporation fresh MEDIUM Haemonetics’ CSL agreement supports a plasma-recovery thesis, but November must supply a quantified revenue contribution and transition timetable. Citi’s September 17 upgrade strengthens analyst support; a weekly close below $91… HALO Halozyme Therapeutics, Inc. MEDIUM Halozyme's royalty-led earnings re-rating rests on the 2026-08-06 guidance increase. A weekly close above the $110.76 high identified on September 11 would confirm another price leg before a weekly close below $98 invalidates it; Argus's… HNI HNI Corporation fresh MEDIUM HNI Corporation’s Steelcase integration could sustain earnings growth despite weak organic sales, but the September 18 close broke the prior shelf. The next quarterly report tests delivery against July’s raised outlook; a weekly close… HNST The Honest Company, Inc. MEDIUM The Honest Company’s margin re-rating depends on Q3 confirming organic growth and profitability excluding tariff refunds. Confirmation requires organic growth of at least 5%, underlying adjusted gross margin of at least 43.8% and unchanged… HOOD Robinhood Markets, Inc. MEDIUM Robinhood Markets' September repricing now includes prediction-market infrastructure alongside on-chain finance. Stronger August activity and a weekly close above $124.72 would confirm continuation; a weekly close below $107 would… HP Helmerich & Payne, Inc. MEDIUM Helmerich & Payne’s crude-led drilling recovery needs fourth-quarter rig activity and margins to meet guidance and adjusted earnings to turn positive. Those results would confirm the operating case; a weekly close below $40 invalidates the… HTFL Heartflow, Inc. MEDIUM Heartflow’s diagnostic revenue growth supports a continuation thesis after its August guidance increase. A weekly close above the $50.43 reference high would confirm the price leg before a weekly close below $42 invalidates it; the next… IAG IAMGold Corporation MEDIUM IAMGOLD’s margin-expansion case depends on Côté lowering costs as gold support weakens. Q3 all-in sustaining costs within the published $2,000–$2,150 per-ounce range and retained annual production guidance would confirm the case before a… IBTA Ibotta, Inc. fresh MEDIUM Ibotta's rally prices a repeatable recovery in digital-promotions revenue; Q3 revenue above $86 million with year-over-year growth would confirm the next leg, unless a weekly close below $33 invalidates it first. IOVA Iovance Biotherapeutics, Inc. fresh MEDIUM Iovance Biotherapeutics' Amtagvi ramp supports a higher 2026 revenue outlook; a company-issued range above $350–370 million by 2026-09-30 would confirm it. An unchanged range or a missed update deadline would invalidate the revision thesis. IREN IREN Limited MEDIUM IREN Limited’s recovery rests on converting contracted AI cloud capacity into operating revenue by 2026-12-31. Management’s $4 billion operating-ARR target settles the conversion case, while a weekly close below $35 invalidates the… KARO Karooooo Ltd. fresh MEDIUM Karooooo's record subscriber additions support a continuation thesis, resolved by a weekly close above $68.71 before a weekly close below $62. The next quarterly report tests whether the July-reported subscriber momentum persists. LFST LifeStance Health Group, Inc. fresh MEDIUM LifeStance Health's margin recovery faces a repeatability test after September's shareholder offering: Q3 must meet August guidance and the annual outlook must hold. A weekly close below $11.00 invalidates the market thesis. LIFE Ethos Technologies Inc. fresh MEDIUM Ethos Technologies’ guidance-durability re-rating depends on meeting its third-quarter outlook despite the TruStage disruption. Revenue of at least $160 million and preservation of the $727–731 million full-year outlook would substantiate… LMND Lemonade, Inc. MEDIUM The $50 shelf has held six weeks: $53.14 on 2026-09-02, RSI(14) 50.6, three reference closes since 2026-08-21 inside a $0.41 band. The state cadence restarted — Florida car 2026-08-26, Kansas renters 2026-09-01, Missouri car plus… MANE Veradermics, Incorporated MEDIUM Veradermics’ oral minoxidil story depends on Study ‘304’ replicating the reported hair-growth benefit by year-end 2026. Failed replication, a weekly close below $85, or the reporting window expiring without results would invalidate the… META Meta Platforms, Inc. MEDIUM Meta Platforms’ AI monetisation story gained a consumer product with Muse’s 2026-09-08 launch. Disclosed external AI revenue or contract value by the 2026-10-28 results would validate the commercial leg; a weekly close below $545 would… MGNI Magnite, Inc. fresh MEDIUM Magnite's connected-TV growth now has an AI advertising catalyst; a weekly close above $25.92 and reaffirmed 2026 guidance at the next quarterly report would validate the next leg. A weekly close below $21 invalidates the price structure. MGTX MeiraGTx Holdings plc fresh MEDIUM The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 — a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but… MTW The Manitowoc Company, Inc. MEDIUM Manitowoc's crane-order recovery supports its re-rating if Q3 backlog holds at least $1,050.1 million and raised 2026 profit guidance survives. A weekly close below $18 invalidates the price thesis; the Q3 reporting date remains… NAVN Navan, Inc. fresh MEDIUM Q2 FY2027 prints 2026-09-09 with the first positive non-GAAP operating-income guide ($13.5–14.5M) on the line. Four target raises in 21 days — BofA $26→$34 on 09-02, Morgan Stanley $33 on 09-04 — landed while the shares fell from the… NET Cloudflare, Inc. MEDIUM Cloudflare’s AI security and agent-infrastructure story supports a recovery toward its recorded $330.83 high. The case plays out on a weekly close above that level by the listed 2026-10-29 results date and fails on a weekly close below… NIQ NIQ Global Intelligence plc MEDIUM NIQ Global Intelligence’s deleveraging re-rating needs a weekly recovery above $19.24 and Q3 delivery against August guidance. A weekly close below $16.00 breaks the price case, while September’s Optiq rollout has yet to establish… NVCT Nuvectis Pharma, Inc. MEDIUM Nuvectis Pharma’s expanded-pipeline valuation depends on US development of its Haisco compounds. The case requires announced IND submissions for both assets and a weekly close above the $28.53 trailing high by 2026-12-31, before a weekly… OMER Omeros Corporation MEDIUM Omeros Corporation’s YARTEMLEA launch supports a further re-rating if Q3 2026 net sales exceed Q2’s $28.5 million before a weekly close below $16.00. The 2026-10-01 hospital reimbursement change adds a later adoption test; it cannot… OPRT Oportun Financial Corporation MEDIUM Oportun Financial Corporation's margin-repair re-rating needs a weekly close above the $8.09 market high and Q3 results meeting its 2026-08-05 guidance. A weekly close below $7.00 or Q3 adjusted EBITDA below $43 million invalidates the… ORKA Oruka Therapeutics, Inc. MEDIUM Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B… PBF PBF ENERGY INC. MEDIUM PBF Energy’s new high prices in sustained refining profits; Q3 adjusted earnings of at least $6.22 per share would confirm the case unless a weekly close below $75.48 first breaks the breakout. PCTY Paylocity Holding Corporation MEDIUM Post-print re-rating leg: the 2026-08-04 Q4 FY26 beat ($1.84 adj. EPS vs $1.61 est.) triggered five price-target raises in 48 hours and a $150.42 close on 2026-08-07, +35.5% over three months. The buy is multiple recovery in mid-cap HCM… PGNY Progyny, Inc. MEDIUM Progyny’s distribution expansion supports a recovery toward Citizens’ $33 target; Q3 revenue tests whether demand stabilizes. A weekly close below $24 or Q3 revenue at or below $335 million would invalidate the recovery case. PLPC Preformed Line Products Company MEDIUM The July rollover read was voided by the 2026-07-29 Q2 print: sales $212.7M vs $193M consensus, EPS $4.49 vs $2.41, and a ~30% one-session repricing to a new all-time closing high of $480.77 (2026-08-11). Grid/AI-power second-order… PLSE Pulse Biosciences, Inc MEDIUM Pulse Biosciences’ faster trial-enrollment story depends on NANOPULSE-AF completion in early October. An announcement by 2026-10-31 before a weekly close below $44 would validate the schedule thesis; the 2026-09-09 analyst initiation adds… PMTS CPI Card Group Inc. MEDIUM Levered card manufacturer re-rating on cash generation: Q2 revenue $149.2M (+15%) with net leverage cut to 2.7x from 3.6x and FY free-cash-flow guidance lifted to $45–50M on 2026-08-06. Adjusted EBITDA grew just 7% against that 15% top… PSX Phillips 66 MEDIUM Phillips 66’s repricing depends on exceptional refining margins persisting into Q3 2026. The case plays out if Q3 realized refining margin reaches at least Q2’s $24.08 per barrel before a weekly close below $239 invalidates it. PUBM PubMatic, Inc. MEDIUM PubMatic's AI-led advertising recovery supports a growth re-rating, conditional on Q3 revenue reaching at least $75 million and a weekly close above the August high of $17.78. A weekly close below $15.20 would invalidate the case. PYPL PayPal Holdings, Inc. MEDIUM PayPal's standalone turnaround rests on profit guidance reiterated on 2026-09-09 despite checkout pressure. The case plays out if the 2026-10-27 results preserve its approximately $5.38 annual adjusted earnings-per-share outlook before a… RCEL Avita Medical, Inc. fresh MEDIUM AVITA Medical’s wound-care turnaround depends on meeting its $86–89 million 2026 revenue guide and generating cash in the fourth quarter. Those commitments, announced on 2026-08-06, must become reported results before a weekly close below… RCMT RCM Technologies, Inc. MEDIUM RCM Technologies’ energy-services re-rating requires continued Engineering growth and stable margins. Q3 revenue above the segment’s $39.5 million Q2 level and consolidated gross margin of at least 25.7% would confirm the case, provided a… RVTY Revvity, Inc. fresh MEDIUM Revvity’s AI drug-discovery story requires instrument backlog to convert into positive Life Sciences organic growth. The next quarterly report must show that recovery while preserving August’s full-year growth outlook before a weekly close… SBET SharpLink, Inc. MEDIUM SharpLink's Ether treasury discount is the recovery thesis: The Block reported a 0.84-times net asset value multiple on 2026-09-07. The case plays out if a comparable valuation reaches net asset value before a weekly close below $7.50… SGMT Sagimet Biosciences Inc. Series A MEDIUM Sagimet Biosciences’ funded acne-trial launch underpins a continuation case, confirmed by October 2026 screening and a weekly close above $11.06. A weekly close below $8.50 or a disclosed screening delay beyond October would invalidate it. SIBN SI-BONE, Inc. MEDIUM SI-BONE’s surgical-device growth and improving adjusted profitability underpin a recovery case above the August shelf. A weekly close above $21.40 would confirm renewed strength before a weekly close below $17 invalidates it; the September… SMMT Summit Therapeutics Inc. fresh MEDIUM Summit Therapeutics’ ivonescimab thesis is that quantified survival evidence converts into US approval by 2026-11-14 before a weekly close below $15.00. September’s disclosures strengthen the clinical case, but the global trial’s primary… SNAP Snap Inc. MEDIUM Snap Inc.'s margin recovery supports a potential rerating above $6; the 2026-09-16 SPECS launch tests renewed attention. The price case succeeds on a weekly close above $6 before a weekly close below $5, while Q3 results test operating… SOPH SOPHiA GENETICS SA fresh MEDIUM SOPHiA GENETICS' cloud-genomics expansion thesis requires renewed strength above the $8.92 market high and another revenue-guidance increase at Q3 results, estimated for 2026-11-03. A weekly close below $6.84 invalidates the price thesis;… SPCX SpaceX (Space Exploration Technologies Corp.) MEDIUM SpaceX’s compute expansion now has a price breakout behind it; September capacity delivery and the December contract start test revenue conversion. A weekly close below $146.15 invalidates the breakout thesis. SPT Sprout Social, Inc MEDIUM Sprout Social's margin-led recovery thesis calls for a weekly close above the market's 2026-08-28 close of $11.49 before a weekly close below $9.50. Q3 results test whether revenue and operating income meet management's 2026-08-06 guidance. SPXC SPX Technologies, Inc. MEDIUM Q2 beat-and-raise on 2026-07-30 was the strongest print of the cycle — HVAC backlog $919M (+59% organic), 2026 data-center revenue set at $430M, capacity target lifted to $1.1B from $750M — yet the 2026-08-14 close of $217.32 sits 11.8%… SRPT Sarepta Therapeutics, Inc. MEDIUM Sarepta Therapeutics’ recovery thesis prices commercial funding of its RNA pipeline, with follow-up clinical data guided for the second half of 2026. The market re-rating case completes at a weekly close above the supplied $24.45 reference… SSL Sasol Limited MEDIUM Sasol Limited’s operating recovery supports price continuation after its 2026-09-01 results. A weekly close above the $14.65 annual high recorded on 2026-09-11 completes the case; a weekly close below that day’s $14.59 reference close… SSRM SSR Mining Inc. MEDIUM SSR Mining’s post-divestiture re-rating rests on cash and repurchases, with weaker momentum after the 2026-09-04 jobs report. A weekly close above the $39.21 market high would confirm the case before a weekly close below $33 invalidates it. STLN Starling Oncology, Inc. MEDIUM Starling Oncology’s oncology-risk contracts support a margin-expansion thesis that the next quarterly results must confirm. Third-quarter adjusted EBITDA within management’s $500,000–$1.5 million range and maintained full-year guidance… TARS Tarsus Pharmaceuticals, Inc. MEDIUM Tarsus Pharmaceuticals’ eye-care expansion depends on XDEMVY sustaining growth after the Alkeus acquisition. The case requires next-quarter sales above Q2 2026’s $173.9 million and retention or an increase of both boundaries of the… TEAM Atlassian Corporation MEDIUM The "agentic AI kills seat-based software" de-rating just reversed: Q4 FY26 (2026-08-06) put cloud +31% and $6,606M subscription ARR behind the Rovo/MCP agent story, and the stock gapped 30%+ on 2026-08-07 to close $149.07. The… TSEM Tower Semiconductor Ltd. MEDIUM Tower Semiconductor’s silicon-photonics expansion needs its next quarterly report to confirm the August revenue guide and July 2028 model. A weekly close below $195 would invalidate the price recovery before that operating confirmation. TVTX Travere Therapeutics, Inc. fresh MEDIUM Travere Therapeutics’ FILSPARI expansion needs another quarter of sales and patient-start growth to confirm its commercial narrative. A weekly close above $67.52 completes the price case; a weekly close below $58 invalidates it. TWLO Twilio Inc. MEDIUM Legacy CPaaS repricing as voice/agentic-AI engagement infrastructure; sell-side re-clustered higher into the print — Cowen $245, Mizuho $240, Citizens $250 (2026-07-17/20) — but the 2026-07-30 Q2 report is now the binary deciding whether… TWST Twist Bioscience Corporation fresh MEDIUM Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since the 2026-05-21 analyst day. Targets now $102-$120 but price sits above the $85.50 consensus and… U Unity Software Inc. MEDIUM Unity Software’s advertising turnaround needs Q3 Strategic Grow revenue of at least $380 million and its promised first GAAP-profitable quarter. Those tests come from management’s 2026-08-06 outlook; a weekly close below $36 would… UGP Ultrapar Participacoes S.A. MEDIUM Ultrapar’s Ipiranga earnings and reported stake-sale talks underpin a further re-rating. A weekly close at or above UBS’s 2026-09-04 target of $7.90 would confirm the price case; a weekly close below $5.80 or confirmed termination of the… VLO Valero Energy Corporation MEDIUM Refiner crack spreads at a record ~$70/bbl 3-2-1 as a Hormuz/Iran supply shock idles ~10% of global refining; VLO is the pure-play margin leverage and the fundamental leg is accelerating. But sell-side (6 PT raises in 11 days) and CNBC… VST Vistra Corp. MEDIUM Vistra's AI-power scarcity story now depends on PJM's September procurement proceeding and a weekly close above the June resistance shelf near $153. A weekly close below $135.66 invalidates the price-repair case. VSTM Verastem, Inc. MEDIUM Verastem’s commercial launch supports a VS-7375 clinical revaluation thesis, tested by the newly scheduled 2026-10-14 efficacy update. The case requires reported tumor responses and a daily close above the 2026-09-02 reference close of… ZLAB Zai Lab Limited MEDIUM Zai Lab's global drug-development re-rating depends on October's zoci data leading to first-line lung-cancer Phase 3 initiation by 2026-12-31. The case requires those milestones before a weekly close below $22; the partnered ALKIVIA… ATI ATI Inc. fresh MEDIUM Titanium/superalloy aero-defense supplier digesting a June breakout above the reclaimed $183.30 ATH shelf: ~9% off the $204.09 high, RSI cooled to ~66, consensus PT $200.33 back above spot. Q2 lands 2026-08-06; peer CRS prints 2026-07-30… NBIS Nebius Group N.V. fresh MEDIUM GPU-neocloud narrative re-accelerated after NVIDIA disclosed a 9.3% stake (7/20) and PT raises followed (Northland $410, Baird initiates Outperform $250); Alphabet's 7/22 "demand outpaces capacity" answers the Meta-Compute bear case. The… RIOT Riot Platforms, Inc. fresh MEDIUM Riot Platforms’ AI-leasing thesis depends on permanent project financing and resolution of interim borrowing before maturity. Binding funding consistent with management’s 2026-08-10 plan would establish delivery financing; a weekly close… RKLB Rocket Lab Corporation fresh MEDIUM Rocket Lab's stabilisation case rests on operating growth absorbing acquisition dilution after its September 15 funding announcement. Iridium approval on 2026-09-24 followed by a weekly close above $64.26 confirms the narrow case only if a… WULF TeraWulf Inc. fresh MEDIUM TeraWulf’s AI-landlord conversion turns on CB-4 earning rent in September 2026 before a weekly close below $14.50. Wells Fargo’s September 17 coverage initiation adds attention, but rental commencement remains unverified as of September 20. ABT Abbott Laboratories fresh MEDIUM Two named overhangs cleared in August and the tape handed the gain back: $112.47 on 2026-08-28 to $108.33 on 2026-09-04, RSI(14) 61.7 to 44.9, with the $103 post-Q2 gap shelf now 4.9% below. The narrative is saturated — retail-facing… ABVX Abivax SA fresh MEDIUM Abivax's recovery case requires a late-2026 obefazimod US filing and a weekly close above the July offering price of $125 by 2026-12-31, before a weekly close below $96 invalidates it. The 2026-09-21 results provide the next scheduled test… ABX Abacus Global Management, Inc. fresh MEDIUM The $9.00 shelf still holds — $9.61 on 2026-09-04 against $9.27 on 2026-08-14, RSI(14) 59.7 — with the $100M repurchase live since 2026-08-17 the only identifiable new bid and no company release since 2026-08-24. What remains is a… ACIW ACI Worldwide, Inc. MEDIUM Special-situation breakup narrative accelerating: Reuters (2026-07-17) reports ACI exploring a ~$1.5B sale of its Biller unit, which would surface sum-of-the-parts value and re-rate the faster-growing Payments Software segment. Q1 beat +… ADBE Adobe Inc. fresh MEDIUM Deep-value AI-disruption leg in legacy software, now with an external validator: the 2026-08-13 Silver Lake–Workday take-private report put a sponsor price on marked-down per-seat SaaS. ADBE closed 2026-08-14 at $264.02, 28.2% off the… ADI Analog Devices, Inc. fresh MEDIUM Analog Devices’ AI and industrial growth story supports a recovery thesis, with fourth-quarter delivery as the operating test. Revenue at or above the $4.3 billion guidance midpoint and a daily close above the supplied $444.13 annual high… AGIO Agios Pharmaceuticals, Inc. fresh MEDIUM Agios Pharmaceuticals' mitapivat label-expansion thesis turns on FDA approval for sickle cell disease by 2026-11-01. Approval would validate the regulatory case; a weekly close below $29 would invalidate the price structure first. AKAM Akamai Technologies, Inc. fresh MEDIUM Legacy-CDN-to-AI-inference pivot got its first external validation since the failed July bounce: Q2 CIS +39% to $99M with >$2.8B YTD contract bookings (2026-08-06), then J.P. Morgan off Underweight to Neutral, PT $158 (2026-08-13). Price… ALAB Astera Labs, Inc. fresh MEDIUM Q2 (2026-08-04) answered the July margin question: GM 73.7% vs ~73% guide, and Q3 guided $540–560M vs $416.5M consensus (~40% QoQ) with Scorpio X switches in volume production a quarter early. Price has not confirmed — the 2026-08-14 close… ALGT Allegiant Travel Company fresh MEDIUM Allegiant closed the $1.5B Sun Country acquisition (2026-05-13) to become the largest US leisure airline just as fuel flipped to a tailwind and the whole sell-side re-rated it to $142–$160; the move has more than doubled off the low, and… ALM Almonty Industries Inc. fresh MEDIUM Non-China tungsten narrative now trades on one venue: the TSX exit took effect 2026-07-31 and the ASX removal 2026-09-01, leaving Nasdaq and Frankfurt. The operating case is unchanged — Sangdong throughput since 2026-07-01, Q2 revenue… AMBA Ambarella, Inc. fresh MEDIUM Physical-AI pure-play narrative still accelerating (Rosenblatt top H2-2026 pick, PT $120; Zacks upgrade to #2 Buy 2026-07-21), but the post-Rosenblatt breakout to ~$80 round-tripped to ~$67.61 by 2026-07-24, forfeiting the $72 shelf on a… AMC Amc Entertainment Holdings, Inc. fresh MEDIUM Box-office recovery flipped from meme-squeeze dormancy to a fundamental earnings inflection: Q2 (2026-07-20) adj EPS $0.14 vs $(0.06) est, revenue $1.597B beat, plus a Wedbush $4 / Benchmark $3 upgrade cluster (2026-07-21). Narrative… ANDG Andersen Group Inc. fresh MEDIUM Post-IPO roll-up re-rate that survived its binary: Q2 revenue $217.7M beat $199.3M on 2026-08-12 and FY2026 was affirmed at $980M–$1.0B, with four target raises to $49–57 on 2026-08-13. The print is behind it and no dated catalyst sits… APPS Digital Turbine, Inc. MEDIUM Digital Turbine’s mobile-advertising recovery supports a renewed re-rating case after the September price rebound. A weekly close above the $14.39 reference high would complete the price case; a weekly close below $9.50 or a cut to fiscal… ARIS Aris Mining Corporation MEDIUM Aris Mining’s expansion case depends on Marmato producing first gold in Q4 2026 with annual production guidance intact. Company confirmation before a weekly close below $17.50 would establish the near-term commissioning leg; first gold… ARXS Arxis, Inc. MEDIUM Arxis’ defense-and-space acquisition story needs another revenue-guidance increase at the next quarterly report to confirm acceleration. The case requires organic growth to hold at the 21% reported on 2026-07-29 and ends first if a weekly… ATEYY Advantest Corporation fresh MEDIUM Advantest Corporation’s AI-testing thesis requires October 28 results to sustain July’s raised forecasts and a weekly close above $216.24 before a weekly close below $200. September 10 foundry growth supports demand indirectly; subsequent… AUR Aurora Innovation, Inc. fresh MEDIUM Q2 (2026-07-29) cleared the binary without breaking the plan: >200 driverless trucks and ~$80M exit run-rate reaffirmed, FY26 revenue guided $14–16M, ~$1.2B cash after a $215M net ATM raise. Price reclaimed the broken ~$6.00 June shelf to… AVTR Avantor, Inc. fresh MEDIUM Avantor’s recovery re-rating depends on Q3 delivering July’s organic growth and adjusted earnings guidance while retaining its improved full-year outlook. That confirmation must arrive before a weekly close below $14.00 breaks the price… AYA Aya Gold & Silver Inc. fresh MEDIUM Aya Gold & Silver's production-growth thesis requires Q3 Zgounder output above 1.49 million silver ounces and processing above 3,889 tonnes per day. Boumadine's September 9 study strengthens the development case, but a weekly close below… BBAR Banco BBVA Argentina S.A. MEDIUM Argentina country trade re-accelerated: June CPI printed 1.9% MoM on 2026-07-14 (first sub-2% of the cycle) and country risk broke to 402bp, tightest since April 2018, carrying BBAR to a fresh 52-week high of $22.47. Price now sits above… BBWI Bath & Body Works, Inc. MEDIUM Bath & Body Works’ cash-flow turnaround needs Q3 sales to decline no more than 2.5% and its approximately $650 million FY2026 free-cash-flow outlook intact. A weekly close below $18 invalidates the structural case before that operating… BE Bloom Energy Corporation fresh MEDIUM Bloom Energy’s AI data-center power thesis now depends on earnings sustaining the September advance after index inclusion. The next quarterly report must preserve its $3.9–$4.2 billion FY2026 revenue outlook and confirm price strength… BETA Beta Technologies, Inc. fresh MEDIUM Beta Technologies' recovery case rests on certification progress converting aircraft backlog into revenue. A weekly close above the September 4 reference of $22.20 would confirm the price recovery; a weekly close below $19.00 would… BHE Benchmark Electronics fresh MEDIUM Beat-and-raise on 2026-07-29 (rev $756M +18% YoY, AC&C +71% YoY, FY26 lifted to ~$3B/+13%) was fully sold: price round-tripped from the $98.67 52-week high to $81.75 on 2026-08-14. The AI-cooling and lidar picks-and-shovels leg is… BILL BILL Holdings, Inc. MEDIUM BILL Holdings’ margin recovery needs customer stabilisation at the next quarterly report after the September 11 close erased August’s rebound. A weekly close above $52 before a weekly close below $44 would confirm the price-recovery case;… BLZE Backblaze, Inc. fresh MEDIUM Neocloud storage pick-and-shovel: the five-year ~$335M CoreWeave B2 Neo deal (2026-06-23) re-rated BLZE from the high-$7s to a 52-week high near $18, and sell-side is still chasing (Citizens to $16, 2026-07-23). Narrative accelerating but… BMA Banco Macro S.A. MEDIUM Banco Macro's sovereign-risk recovery gained support from August inflation of 1.7%, released September 10. The price case plays out on a weekly close above September 4's $78.57 before a weekly close below $72; Q2 credit deterioration still… BMY Bristol-Myers Squibb Co. fresh MEDIUM Post-guidance-reset re-rate printed a new 52-week high of $68.09 before the 2026-09-04 close of $66.82, but the first negative company headline of the leg — the zola-cel autoimmune CAR-T enrollment pause confirmed 2026-08-31 — arrived with… BOLD Boundless Bio, Inc. fresh MEDIUM Boundless Bio’s merger thesis pairs a planned $44–48 million cash distribution with a minority Serapha interest. Completion by 2026-12-31 with that distribution intact would confirm the case; a weekly close below $2.40 would invalidate its… BTU Peabody Energy Corporation MEDIUM Peabody Energy’s Centurion recovery depends on higher production becoming shipments and positive metallurgical earnings. Third-quarter sales meeting management’s 0.5–0.7 million-ton range and positive segment adjusted EBITDA would… CBLL CeriBell, Inc. MEDIUM Ceribell’s reimbursement-backed delirium expansion needs a Q4 2026 commercial launch and a weekly close above $24.89 to confirm the next leg. A weekly close below $21.50 invalidates the price thesis; the 2026-10-01 payment start alone does… CCC CCC Intelligent Solutions Holdings Inc. MEDIUM Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is… CERT Certara, Inc. MEDIUM The self-help leg is intact and quiet: FY26 guidance was reaffirmed at the 2026-08-04 Q2 print ($367–382M revenue, $0.31–0.36 adj EPS), the ~$13M cost takeout first shows up in Q3 numbers, and the shares have held four closes between $8.13… CGEM Cullinan Therapeutics, Inc. fresh MEDIUM CD19 T-cell-engager-in-autoimmune narrative re-rated CGEM ~3x off the $5.68 low on CLN-978 lupus/RA single-dose remissions; now drifting to ~$17.10 in a bull flag under the $19.43 high with the big data catalyst spent and no dated readout… CLOV Clover Health Investments, Corp. fresh MEDIUM Clover Health's rating-led profitability thesis has fresh analyst coverage but still depends on the court-supported reimbursement remedy. A weekly close above the $5.41 reference high with its raised FY2026 outlook intact would confirm… CMCO Columbus McKinnon Corporation MEDIUM First full combined quarter post-Kito Crosby beat hard (adj EPS $0.61 vs $0.27 est) and drove a guidance raise on all three lines on 2026-07-30; the leg being bought is deleveraging from 4.9x toward sub-4x by FY28 on $70M of synergies. No… CME CME Group Inc. MEDIUM CME Group's product-launch story requires its September–October factor, hockey and compute contracts to begin trading on schedule. Missed launch dates or a weekly close below $272 would invalidate the near-term case. COHU Cohu, Inc. MEDIUM Best fundamental print of the AI cycle (2026-07-30: rev $149M vs $144.08M cons.; Q3 guided $163–177M vs $146.33M) collided with a sector de-rate — the stock closed $52.88 on 2026-08-07, 28.5% under its $73.91 high and beneath the June… COTY COTY INC fresh MEDIUM Balance-sheet repair, not demand recovery: FY26 net debt fell to $2,912.1M but leverage still printed 3.4x as adjusted EBITDA fell 22% to $846.9M, and the 2026-08-19 print deferred FY27 guidance to the end-CY26 Consumer Beauty review. The… CRAI CRA International, Inc. MEDIUM Beat-and-raise from 2026-08-06 — record $210.8M quarter, FY26 constant-currency guide to $805–820M — remains only partly repriced: $174.99 on 2026-08-28, 20.8% under the $221.02 high, no company headline since 2026-08-08. The leg is a toll… CRDO Credo Technology Group Holding Ltd MEDIUM Interconnect/AEC royalty narrative still accelerating, not fading — new 52-week highs on late-June initiations (Evercore $325, Stifel $350, BofA $340) plus the early-July AI-buildout rally. But it's now mainstream and widely held, entering… CSTL Castle Biosciences, Inc. fresh MEDIUM Castle Biosciences’ recovery rests on TissueCypher sustaining its growth plan; the next quarterly results must preserve revenue and test-volume guidance. Management’s unchanged outlook at the 2026-09-15 Baird conference supports the case,… CTOS Custom Truck One Source, Inc. MEDIUM Utility T&D / grid-capex cycle with CTOS as the laggard specialty-rental picks-and-shovels name; the June breakout to $11.36 has stalled, retracing ~10% to retest the ~$10 shelf into a binary 2026-07-29 Q2 print. Theme now maturing and… CTRN Citi Trends, Inc. fresh MEDIUM The 2026-08-25 print resolved the binary the right way — comps +10.5%, gross margin 40.6% (+60bps), FY adjusted EBITDA guide lifted to $38–42M — and the shares still closed lower, because the raised FY sales range of $901.958M–$918.357M… CXT Crane NXT, Co. fresh MEDIUM The post-print give-back stopped rather than reversed: $50.20 on 2026-08-21 and $50.06 on 2026-09-04, RSI back to 49.5, with the $47 washout shelf untested since the 2026-08-19 $48.06 open. The sell-side anchor reset lower in the same… DFDV DeFi Development Corp. fresh MEDIUM DeFi Development Corp.'s preferred financing creates a path to more Solana per common share. A subsequent issuer disclosure above the August 12 figure of 0.066 SOL per share would confirm that leg; a weekly close below $4.90 invalidates it. DFIN Donnelley Financial Solutions, Inc. MEDIUM Donnelley Financial Solutions’ software transition supports margin expansion; Q3 must match Q2’s 7.8% software growth, exceed $175 million revenue and deliver at least a 26% adjusted EBITDA margin before a weekly close below $44… DGII Digi International Inc. fresh MEDIUM Hardware-to-ARR re-rating accelerating: the 2026-08-05 Q3 print put ARR at $191M (+52% YoY) with a record 29.1% adj-EBITDA margin, and FY26 revenue guidance jumped to $529–533M from $490–508M. Price closed 2026-08-14 at $85.12, 0.1% off… DOCN DigitalOcean Holdings, Inc. MEDIUM DigitalOcean’s AI cloud recovery needs third-quarter revenue of $304–$307 million, its August 4 guidance, and a weekly close above the former $132 August shelf. A weekly close below the July placement price of $117.54 invalidates the case. DOCU DocuSign, Inc. MEDIUM DocuSign’s AI agreement pivot now has higher analyst targets behind it; a weekly close at or above Piper Sandler’s September 4 target of $75 would confirm the repricing, while a weekly close below $64 would invalidate it. DRTS Alpha Tau Medical Ltd. MEDIUM Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +… DVA DaVita Inc. MEDIUM The census-recovery re-rate stayed dead through August, but the 2026-08-21 washout close of $173.82 held: DVA closed 2026-08-28 at $180.68 with RSI(14) back to 44.9 from 10.9. The 2026-08-25 Humana value-based deal (>10,000 MA members, CKD… DXC DXC Technology Company MEDIUM DXC Technology’s AI pivot is a recovery thesis: September-quarter results must meet guidance and preserve the annual earnings outlook. A weekly close below $10.50 invalidates the price structure supporting the case. DYN Dyne Therapeutics, Inc. MEDIUM Nothing company-dated until the ~late-October Q3 print, leaving a maturing narrative to trade on small-cap biotech flow ahead of the 2027-01-21 PDUFA. EDRY EuroDry Ltd. fresh MEDIUM EuroDry’s freight-led revaluation needs third-quarter charter earnings to sustain the second-quarter level. Confirmation requires reported TCE of at least $20,398 per vessel per day before a weekly close below $57.43; Panamax earnings of… ELF e.l.f. Beauty, Inc. fresh MEDIUM Sell-side flipped from cutting to marking up in ten days — five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative… ENTG Entegris, Inc. MEDIUM June's sentiment re-rate rolled over; the 2026-08-04 beat-and-raise re-based the story on numbers — Q2 sales $883.2M vs $835.5M consensus, Q3 guide $905–935M vs $879.8M — and drew three target raises on 08-05 (UBS $215). At $152.08 the… FET Forum Energy Technologies, Inc. MEDIUM Forum Energy Technologies’ operating-leverage re-rating needs Q3 revenue of $225–245 million and retained full-year guidance. Those results plus a weekly close above the September 11 reference high of $86.31 would confirm the case; a… FIGR Figure Technology Solutions, Inc. fresh MEDIUM Figure Technology Solutions' Kiavi expansion needs Q3 marketplace volume to meet the $4.8–5.2 billion guidance excluding Kiavi while preserving Q2's 55% adjusted EBITDA margin. A weekly close below $30 or failure of either operating test… FORM FormFactor, Inc. MEDIUM Probe-card pick-and-shovel to the HBM4 test ramp; after a parabolic run to a fresh $160.27 ATH (2026-06-30) on Russell 1000 inclusion, the 2026-07-02 chip selloff cut FORM ~24% to ~$121. HBM inflection intact (record DRAM quarter, second… FSLR First Solar, Inc. fresh MEDIUM Section 232 supplied a new leg: the 2026-08-06 proclamation sets a $0.38/W minimum import price on modules from 2026-12-04, above the ~$0.36/W FSLR struck on Q2 US bookings. Baird upgraded 2026-08-11 with a target moved to $318 from $205.… FTRE Fortrea Holdings Inc. fresh MEDIUM Fortrea’s margin-repair recovery requires backlog growth and preservation of the $205 million full-year adjusted-EBITDA floor at the next quarterly report. The September 18 shelf recovery supports the case, which a weekly close below… GCMG GCM Grosvenor Inc. fresh MEDIUM GCM Grosvenor’s recurring-fee growth supports a revaluation, conditional on the next report sustaining FRE growth and fundraising. Confirmation requires quarterly fundraising at least matching Q2’s $2.3 billion and a weekly close above the… GCT GigaCloud Technology Inc MEDIUM GigaCloud Technology's operating-leverage rerating remains the thesis; a weekly close above $53.25 would confirm price continuation, while a weekly close below $45 would invalidate it. Third-quarter results test whether the August margin… GERN Geron Corporation fresh MEDIUM The leg is a self-funding commercial ramp, not the myelofibrosis binary: Q2 RYTELO revenue $57.5M (+11% QoQ), quarterly cash draw down to ~$14M on $326.9M, FY guide $220–240M reiterated at the mid-to-high end. The 2026-09-02 release added… GH Guardant Health, Inc. fresh MEDIUM Guardant Health’s renewed advance prices broader Shield coverage becoming screening revenue. The next quarterly screening result must exceed Q2’s $52.9 million, reported on 2026-07-30; a weekly close below the 2026-09-04 reference close of… HIMX Himax Technologies, Inc. MEDIUM Himax Technologies' AI-sensing re-rating requires a named, shipping smart-glasses product and Q3 revenue meeting its August 6 guidance before a weekly close below $13. The September 11 reclaim of the post-earnings reference close improves… HPK HighPeak Energy, Inc. MEDIUM HighPeak Energy’s second-half spending reduction supports a debt-reduction thesis that third-quarter accounts must confirm. The case resolves with lower capital spending and total debt below June’s approximately $1.19 billion before a… HRI Herc Holdings Inc. MEDIUM Second-order AI/power play: Herc rents the cranes and gensets that build data centers. Peer United Rentals raised FY26 guidance (2026-04-23), confirming an accelerating theme — but the stock sits +71% off its low and drifts into a binary… HTZ Hertz Global Holdings, Inc MEDIUM The 2026-08-06 Q2 beat re-lit a squeeze the index deletion had just flushed: adjusted corporate EBITDA $81M cleared the top of a $50–80M guide, GAAP swung to +$64M, and the stock ran roughly 50% in two sessions amid 73.85%-of-float short… HUBS Hubspot, Inc. MEDIUM HubSpot is trading as laggard beta on the Salesforce-led software re-rate — CRM +22.6% on 2026-08-27 — carrying HUBS from $240.01 on 08-21 to $260.68 on 08-28 with no company disclosure since the 2026-08-05 guidance reset. Price now sits… ICLR ICON plc MEDIUM ICON plc’s restatement-discount recovery depends on bookings sustaining its earnings outlook. A weekly close above the August reference of $172.23 and unchanged guidance at the next quarterly disclosure would confirm renewed recovery; a… IDYA IDEAYA Biosciences, Inc. fresh MEDIUM IDEAYA Biosciences' darovasertib filing and expansion trials underpin a recovery thesis. Confirmation requires a weekly close above the $42.48 reference high and NDA completion by 2026-12-31 before a weekly close below $34; the October… IMAX Imax Corp MEDIUM IMAX Corporation's record summer supports renewed premium-format repricing; a weekly close above $54.79 would confirm the case. A weekly close below $47 would invalidate it, while the next quarterly results test whether summer demand… IMOS ChipMOS TECHNOLOGIES INC. MEDIUM Memory-cycle re-rating in an AI costume just re-accelerated: June 2026 revenue +37.2% YoY and Q2 +28.7% YoY (both records since 2014, reported 2026-07-10) erase the May deceleration scare, and price bought back the ~17% fade to sit ~$68… INFQ Infleqtion, Inc. fresh MEDIUM Infleqtion’s Cisco collaboration and NVIDIA software work refresh its funded-quantum story. A daily close above $13.60 by 2026-10-07 would validate the near-term price response; a daily close below $10.90 would invalidate it. INNV InnovAge Holding Corp. fresh MEDIUM InnovAge’s September earnings beat shifts the turnaround story to fiscal 2027 growth. A weekly close above the $12.11 reference high with its 2026-09-08 outlook intact would confirm the next advance; a weekly close below $10.50 invalidates… IRWD Ironwood Pharmaceuticals, Inc. fresh MEDIUM Ironwood Pharmaceuticals’ LINZESS cash generation supports a recovery toward the market’s $5.39 high, tested by annual guidance and year-end debt reduction. A weekly close above $5.39 completes the price case; a weekly close below $3.80… IVA Inventiva S.A. fresh MEDIUM The 30-day news blackout broke: the 2026-09-02 last-patient-last-visit release in NATiV3 (1,419 patients) reaffirmed Q4 2026 topline and closed the trial-conduct timing gate, leaving database lock and unblinding as the only steps before… JRSH Jerash Holdings (US), Inc. fresh MEDIUM Jerash Holdings’ sourcing-migration story depends on another quarter meeting guidance. Fiscal Q2 revenue of at least $49 million and gross margin of at least 14% would confirm the case before a weekly close below $4.80 invalidates the… KEYS Keysight Technologies, Inc. fresh MEDIUM Analyst-migration re-rate's second leg (Morgan Stanley to Overweight, PT $400, 2026-07-13) has stalled — silent tape near 28x forward, empty calendar until the ~2026-08-19 Q3 FY26 print. The $290–300 breakout-shelf entry hasn't come;… KMX CarMax Inc. fresh MEDIUM Turnaround re-rating went live in July: KMX broke the $50–$53 shelf to close $57.33 on 2026-07-17 (+17.2% in five sessions) after a Q1 FY27 blowout (EPS $1.31 vs ~$0.95, revenue $8.01B +6.2%), CEO Keith Barr buying 9,400 shares at $53.005… KNSA Kiniksa Pharmaceuticals International, plc MEDIUM Kiniksa Pharmaceuticals’ commercial re-rating depends on another ARCALYST revenue-guidance increase at the next quarterly report. The case fails if that report leaves the 2026-07-28 range of $980–995 million unchanged or lower, or a weekly… KOPN Kopin Corporation fresh MEDIUM Kopin Corporation's defense orders and optical-interconnect pivot support a recovery case toward the $6.39 market high recorded as of 2026-09-18. The forecast succeeds if that high is reached by the next quarterly report, estimated for… LGND Ligand Pharmaceuticals Incorporated fresh MEDIUM Ligand Pharmaceuticals’ royalty growth and XOMA integration support an earnings-compounding case. A weekly close above $322.61 before a close below $262, accompanied by a December 8 outlook preserving the projected 2027 XOMA contribution,… LILA Liberty Latin America Ltd. fresh MEDIUM Liberty Latin America's break-up story needs an announced Puerto Rico and US Virgin Islands separation form and completion window by the next quarterly report. That milestone confirms the case unless a weekly close below $7.30 invalidates… LNC Lincoln National Corp. MEDIUM Lincoln National Corporation’s legacy-risk transfer supports a re-rating case, with Talcott completion in Q4 2026 and a weekly close above $47 confirming it. A weekly close below $42 or failure to close the deal by 2026-12-31 invalidates… MBX MBX Biosciences, Inc. fresh MEDIUM MBX Biosciences' funded once-weekly hormone-replacement program anchors the valuation story, with Q4 2026 obesity data the next clinical test. The price case requires a weekly close above the $70.70 reference high before a weekly close… MCS The Marcus Corporation MEDIUM Theatrical-recovery re-rating is drifting sideways with no company input: no release and no target revision since 2026-08-04, leaving consensus at $32.25 while the 2026-08-28 close of $29.02 sits 6.5% under the $31.03 52-week high.… MEI Methode Electronics fresh MEDIUM Data-center power pivot is revenue-confirmed — record >$80M FY26 segment sales and an FY27 guide ($1.025–1.075B vs ~$952M Street) — but the post-print momentum leg has faded ~26% from the $20.38 high to ~$15. The re-rate is spent and the… MIRM Mirum Pharmaceuticals, Inc. fresh MEDIUM Rare-disease franchise ran to a $125 ATH on FOP data, then cooled ~9% into a confirmed 2026-07-30 Q2 print. Base compounds (Q1 sales +43% YoY, FY guide $660–680M) with FOP PDUFA 2026-09-26 and HDV Phase 3 topline 2H26 stacked ahead — but… MMED MiniMed Group, Inc. fresh MEDIUM MiniMed Group’s standalone-growth revaluation now has a dated separation test after Medtronic’s September 14 exchange-offer launch. The case succeeds with completion and a weekly close above the September 4 reference close of $23.29 before… MNPR Monopar Therapeutics Inc. fresh MEDIUM The rolling-NDA leg rebuilt without news: $107.72 on 2026-08-21 to $117.56 on 2026-09-04, back within 5.1% of the $123.84 high, on no company release since 2026-08-19 and with two directors selling into $109–$113 on 2026-08-25 and… MYRG MYR Group, Inc. fresh MEDIUM AI/datacenter power-buildout supercycle lifting grid/electrical contractors; MYRG confirmed it with a record Q1 and a late-June breakout to fresh ATHs (~$487) above the $484.71 shelf. Theme accelerating + cluster-confirmed, but the Q2… NEOG Neogen Corporation MEDIUM Neogen’s turnaround rests on Food Safety growth and Genomics-funded debt reduction. The confirmed 2026-10-07 investor day precedes the estimated October results test; a revenue miss, lost sale funding or a weekly close below $11.00 would… NKTR Nektar Therapeutics fresh MEDIUM M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh… NOG Northern Oil and Gas, Inc. MEDIUM Northern Oil and Gas’s crude-driven recovery faces a cash-flow test as hedges limit oil-price upside. A weekly close above the $29.64 annual high completes the price case, while a weekly close below $23.00 invalidates it; third-quarter… NTSK Netskope, Inc. MEDIUM Netskope's September 2 revenue beat and guidance raise support an earnings-backed recovery toward J.P. Morgan's 2026-09-03 target of $18. A weekly close above $18 completes the price case; a weekly close below $13.50 invalidates it. NWL Newell Brands Inc. fresh MEDIUM Post-print re-rating still shelved: the 2026-09-04 close of $6.11 sits 2.8% under the $6.29 52-week high with RSI(14) at 53.2, and the covering leg behind the 7/31 +15% is largely spent (10.52% of float short at the 2026-08-14 settlement,… NXT Nextpower Inc. fresh MEDIUM Falling knife has based and turned: after a -34% unwind from the $163 high to a ~$107 June base, a fresh cluster (Truist initiate Buy $140 07-14, Guggenheim upgrade Buy 07-15) plus a 07-15 surge is re-rating the M&A-drift story. The… ONC BeOne Medicines Ltd. fresh MEDIUM BeOne Medicines’ BRUKINSA growth supports a renewed-high thesis, but September price action has not confirmed it. A weekly close above the supplied $377.47 high would establish the price outcome; a weekly close below $326 would invalidate… OOMA Ooma, Inc. MEDIUM Ooma’s business-communications roll-up faces a September 29 test of its raised $332.0–333.5 million fiscal 2027 revenue outlook. Sustained guidance and a subsequent weekly close above the September 11 reference high of $23.38 would confirm… OWL Blue Owl Capital Inc. MEDIUM Private-credit-stress bottom trade picked up a second strand: Blue Owl managed funds led a $2.4B GPU-equipment financing for IREN on 2026-08-28, days after Oppenheimer took its target to $17. Price closed $12.02 on 2026-08-28, 5% below the… OXM Oxford Industries, Inc. fresh MEDIUM Setup inverted since the June breakdown. OXM reclaimed its 200-day ($39.11) and 50-day ($39.94) off the $35.83 low, the CEO bought 2,500 shares at $36.90 on 2026-06-12, and ~$25M of filed IEEPA tariff-refund claims — 4% of market cap,… P Everpure, Inc. fresh MEDIUM Everpure’s hyperscaler expansion supports a recovery thesis that needs quantified fiscal-2028 revenue at the September 23, 2026 analyst meeting and a weekly close above $110. A weekly close below $92 invalidates the case. PARR Par Pacific Holdings, Inc. fresh MEDIUM Par Pacific's distillate-margin story now depends on Q3 operating confirmation as inventories rebuild from scarce levels. A weekly close above $86.49 would confirm price continuation; a weekly close below $76 would invalidate it. PD PagerDuty, Inc. fresh MEDIUM The read has flipped from value trap to ownership story. Price reclaimed the 200-DMA (~$10.30 on 2026-07-17, +13% in three weeks), Truist lifted its PT to $11 on 2026-07-09, and the 2026-07-14 addition of Alex Shootman — who sold Workfront… PEB Pebblebrook Hotel Trust fresh MEDIUM Pebblebrook Hotel Trust’s lodging recovery requires October 29 results to sustain its raised earnings outlook before the $16 breakout shelf fails. The case resolves positively if third-quarter RevPAR growth exceeds +1% and annual guidance… PENG Penguin Solutions, Inc. fresh MEDIUM Q3 (July 7) broke the model wide open: revenue $478.7M vs $405.5M consensus (+48% YoY), EPS $0.84 vs $0.54, FY26 growth guide lifted 12%→22% and FY27 pre-guided ~30%. The stock then round-tripped from $89.86 to ~$60 on the $750M… PENN PENN Entertainment, Inc. fresh MEDIUM Q2 (2026-08-06) kept the digital turnaround on schedule — interactive adj-EBITDA loss $9.5M (+$52.5M YoY), Q4-2026 profitability target and $1.963B retail EBITDAR midpoint intact — but the tape decoupled: prediction-market headlines took… PGEN Precigen, Inc. fresh MEDIUM PAPZIMEOS launch-ramp durability is the binary — the first FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026, and the now-confirmed Aug 4 Q2 print (announced Jul 21) grades whether the ramp compounds sequentially or… PLMR Palomar Holdings, Inc. fresh MEDIUM Palomar Holdings' $270–280 million FY2026 adjusted-income guidance, issued August 4, anchors the specialty-insurance growth thesis. Confirmation requires a weekly close above $144.79 before a weekly close below $128 invalidates it. PNRG PrimeEnergy Resources Corporation fresh MEDIUM Geopolitical crude bid re-fired after the 2026-07-08 US strikes and Hormuz blockade — WTI back to ~$80 from $68.86, PNRG +8.9% MTD to $186.51 and above the 200-day. Structurally better than June: GCX in-service flipped Waha gas positive,… PRCH Porch Group, Inc. fresh MEDIUM Reciprocal-pivot re-rate has largely printed: $9.26 (6/5) to $15.98, now consolidating at $13.68 after KBW's 7/13 valuation downgrade that still raised its target to $16.25. Narrative intact but maturing; the 2026-08-04 Q2 print is the… PRGS Progress Software Corporation fresh MEDIUM Disciplined software roll-up ("Total Growth Strategy") re-rated by a fresh catalyst cluster: Q2 beat + FY guide raise (2026-06-30) and the $400M Domo buy (2026-07-22). Special-situations theme active, but a maturing low-beta compounder —… PRM Perimeter Solutions, Inc. fresh MEDIUM Monopoly wildfire retardant (PHOS-CHEK) into a season at national Preparedness Level 5 — 3.85M acres burned YTD (NIFC, 7/18), ~157% of the 10-yr average. JPM initiated Overweight $50 on 7/9, lifting the 4-analyst average target to $45.… PTGX Protagonist Therapeutics, Inc. fresh MEDIUM De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs —… PVLA Palvella Therapeutics, Inc. fresh MEDIUM Palvella Therapeutics’ QTORIN filing puts an accelerated FDA review in focus. Acceptance with Priority Review and a weekly close above $157.77 would complete the case before a weekly close below $137 invalidates it; the filing… RAPP Rapport Therapeutics, Inc. fresh MEDIUM RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news — the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.… RDIB Reading International Inc fresh MEDIUM Reading International’s asset-sale deleveraging thesis turns on completing the contracted $41.0 million cinema-property sale around 2026-10-30 and discharging its mortgage. A weekly close below $12 would invalidate the market case before… RELY Remitly Global, Inc. fresh MEDIUM Operating-leverage leg intact but stalling: since the 2026-08-05 Q2 raise to $1.978–1.988B / $410–415M, the only new information has been supply — a Form 4 dated 2026-08-26 shows CFO Mehta selling 25,000 shares at $26.15, one dated… RGEN Repligen Corporation fresh MEDIUM Repligen's bioprocessing recovery and BioLife deal support a breakout thesis above the $182.03 market high. BioLife approval on 2026-10-05 and a weekly close above that high would confirm the next leg; a weekly close below $158 would… RLYB Rallybio Corporation fresh MEDIUM Rallybio’s Avenzo merger thesis combines a cash distribution with residual oncology exposure; completion and a declared distribution would establish the outcome. A weekly close below $14 invalidates the price case, while failure to close… RMAX Re/Max Holdings, Inc. fresh MEDIUM Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80… RNG Ringcentral, Inc. fresh MEDIUM RingCentral’s AI pivot needs paid-adoption growth and delivery against quarterly revenue guidance to substantiate its rerating. The price case is a weekly close above the $76.36 reference high before a weekly close below $64; the next… RRGB Red Robin Gourmet Burgers, Inc. fresh MEDIUM Deleveraging turnaround repricing: ~$96M / 116-unit refranchising cuts net debt ~$147M→~$51M, removing the going-concern tail that pinned RRGB near $2.46. Tape +38.7% since the ~2026-05-20 Q1 print, into the low-$7s near the $7.89 high.… S SentinelOne, Inc. fresh MEDIUM SentinelOne's AI-security story has regained market support after September's Cybersecurity rally, despite the August earnings-guidance cut. A weekly close above the $23.84 reference high would complete the price-recovery case; a weekly… SCZM Santacruz Silver Mining Ltd. fresh MEDIUM Santacruz Silver's producer re-rating rests on deferred concentrate sales becoming revenue and added milling capacity reaching production. Q3 shipment disclosure and management's 2026-12-31 commercial-production milestone settle those… SE Sea Limited fresh MEDIUM Three-engine re-acceleration — Shopee GMV +30%, Monee loan book +71%, Garena's best quarter in 5 years — drove a Q1 beat (2026-05-12) and a +19% one-month recovery off the $77 low. Fundamentally accelerating, but the stock is short-term… SEPN Septerna, Inc. fresh MEDIUM Septerna’s funded oral-drug platform underpins a recovery thesis after the September 18 shelf reclaim. A weekly close above the $48.19 market high before a weekly close below $33 would confirm the price case; clinical validation still… SM SM Energy Company MEDIUM SM Energy’s merger-integration story supports a further rerating. The price case is a weekly close above Wells Fargo’s $47 target of 2026-08-13 before a weekly close below Seaport’s $35 target of 2026-09-03; neither analyst valuation is… SMRT SmartRent, Inc. fresh MEDIUM RSI(14) cooled 87.8→74.7 while price only slipped $1.49→$1.43, so the momentum extreme unwound sideways. Still no dated catalyst until the ~November Q3 print. SNDX Syndax Pharmaceuticals, Inc. MEDIUM Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance… SPSC SPS Commerce, Inc. MEDIUM De-rating-repair leg: Q2 (2026-07-30) beat on adjusted EPS $1.27 vs $1.09 with EBITDA +19% on 6% revenue growth, while the FY26 revenue band was cut on the 2026-06-30 3P divestiture. Price reclaimed the ~$70 200-day, but the fresh Morgan… STRL Sterling Infrastructure, Inc. fresh MEDIUM Sterling Infrastructure’s data-center construction story now rests on recovering the failed $550 shelf while preserving its raised earnings guidance. A weekly close above $550 would establish the recovery case; a weekly close below $465… SWKS Skyworks Solutions, Inc. fresh MEDIUM Skyworks Solutions' Qorvo merger story supports further repricing, with a weekly close above the September 18 high of $91.32 defining success. A weekly close below $84.40 invalidates the price thesis; completion beyond calendar 2026 would… TBLA Taboola.com Ltd. fresh MEDIUM Legacy open-web ad network repricing as a toll booth on AI answer surfaces: the 2026-06-16 DeeperDive ad-network launch (35% take rate, open to third-party LLMs/agents) plus the 2026-07-01 Wikitree win drove a breakout to 52-week highs… TK Teekay Corporation Ltd. MEDIUM Teekay Corporation’s record tanker earnings support price continuation beyond its September 11, 2026 high of $14.38. A weekly close above $14.38 confirms that narrow case; a weekly close below $14.38 invalidates it. TOI The Oncology Institute, Inc. fresh MEDIUM Starling Oncology’s delegated-care expansion supports a profitability re-rating if Q4 2026 contracts launch and FY2026 adjusted EBITDA meets the company’s $2 million floor. A weekly close below $5.13 invalidates the market thesis. TRVI Trevi Therapeutics, Inc. fresh MEDIUM Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional… TTMI TTM Technologies, Inc. MEDIUM The 2026-08-05 binary resolved bullishly — Q2 revenue $1.004B beat both the $930–970M guide and $962M consensus, book-to-bill rose to 1.49, Q3 guided $1.100–1.140B vs $1.073B consensus. Yet the 2026-08-14 close of $140.0 is 36.8% below the… TXN Texas Instruments Incorporated MEDIUM Texas Instruments’ analog and data-center recovery needs Q3 revenue to meet its July guidance and a weekly close above $272. A weekly close below $250 or Q3 revenue below $5.65 billion would invalidate the case; the September 11 close of… ULCC Frontier Group Holdings, Inc. fresh MEDIUM Fuel-relief leg replaced by an earnings-delivery leg: the 2026-07-29 Q2 print put adjusted EPS at $(0.10) against a $(0.60)–$(0.45) May guide on record $1,279M revenue, and guided 2H to breakeven-or-better. The catch is that guide assumes… UROY Uranium Royalty Corp. MEDIUM Uranium Royalty Corp.’s Sweetwater expansion needs cash-flow confirmation. Positive operating cash flow and disclosed Sweetwater royalty revenue, alongside a weekly close above the August 21 reference of $4.38, would substantiate the case… USO United States Oil Fund, LP MEDIUM The driver rotated: Rubio's 2026-08-25 shift from strikes to sanctions drained the escalation bid, but EIA's 0.095M bbl crude build vs 1.600M expected (08-26) and oil rigs -5 to 447 vs 454 est (08-28) carried USO to $129.70. The narrative… VCYT Veracyte, Inc. fresh MEDIUM Sell-side is now chasing a move it missed: VCYT broke to a 52-wk high $60.91 (closed $59.13 on 2026-07-17, +124% YoY) as Piper initiated Overweight $66 (07-15) and Canaccord lifted a Hold PT $42→$60. Fundamentals still accelerating (Q1 rev… VET Vermilion Energy Inc. MEDIUM Vermilion Energy’s European gas revaluation needs Q3 cash flow to confirm the September price recovery. The case plays out if Q3 free cash flow exceeds C$122 million and production meets 116,000–118,000 boe/d before a weekly close below… VG Venture Global, Inc. MEDIUM LNG-export narrative re-accelerating on Europe's winter gas scramble plus a Middle East risk premium; VG ran +23% off the $12 mid-July shelf to $14.31 as Plaquemines ramps and CP2 advances. The 2026-08-11 pre-market Q2 print is the binary… VIA Via Transportation, Inc. fresh MEDIUM Via Transportation's transit-software re-rating depends on meeting Q3 revenue guidance and preserving its Q4 adjusted-profitability goal. A weekly close below $24, Q3 revenue below $137.6 million, or withdrawal of the positive Q4 adjusted… VRA Vera Bradley, Inc. fresh MEDIUM Vera Bradley’s September earnings rally prices in a turnaround; a weekly close above the observed $4.26 annual high before a weekly close below $3.98 would confirm the next price leg. That outcome would establish price continuation, not a… VRNS Varonis Systems, Inc. fresh MEDIUM Varonis Systems' takeover story depends on reported Proofpoint talks producing a signed offer above the September 18 close of $47.56. A weekly close below $41 or confirmed termination of the talks invalidates the thesis. WDAY Workday, Inc. fresh MEDIUM The 2026-08-27 print removed the fundamental leg of the bear case — cRPO +14.2% inside the guided 13.5–14.5% band, FY27 margin guide lifted to 31.0%, a new $4.0B buyback — while the Q3 cRPO guide of 11–12% sits under the ~13.3% consensus.… WEX WEX Inc. MEDIUM Hated fuel-card/fintech inflecting: the 2026-07-22 Q2 beat (Adj EPS $5.35 vs $5.05) and FY26 guide raise to $19.68-$20.08 discredit the EV-kills-fuel-cards and rate-cut-kills-float bear case; PTs jumped to $200-210 (Mizuho/KBW, 7/24).… WIX Wix.com Ltd. fresh MEDIUM Base44 margin inversion is the live leg and the market is now paying up for it: after the 2026-08-04 beat ($563.1M, +15%; adj EPS $1.39 vs $1.16) and the ~60% 2H gross-margin guide, price ran from the 2026-08-07 close of $60.20 to $66.14… WK Workiva Inc. fresh MEDIUM Workiva's earnings re-rating now rests on a higher margin target and paid AI adoption. Q3 delivery against guidance and a weekly close above the 2026-09-04 reference close of $76.55 would confirm the case; a weekly close below $70… WNC Wabash National Corp. MEDIUM Wabash National Corporation’s tariff-supported recovery depends on backlog converting into narrower losses. The case requires an affirmative final China injury decision and Q3 delivery against July 29 guidance before a weekly close below… WTTR Select Water Solutions, Inc. MEDIUM Select Water Solutions’ contracted water-infrastructure transition supports a recovery toward its September 11 reference high of $22.18. A weekly close above that level confirms the price case; a weekly close below $18 invalidates it,… XGN Exagen Inc. fresh MEDIUM Post-print re-rating off the 2026-08-04 Q2 beat (revenue $19.941M vs $17.817M consensus, FY26 guide lifted to $72–75M) is now digesting rather than extending: $7.92 on 2026-08-21 to $7.58 on 2026-09-04 with RSI(14) cooling from 86.7 to… YETI YETI Holdings, Inc. MEDIUM Tariff-margin-recovery turnaround now getting sell-side confirmation: Goldman upgraded to Buy/$63 on 2026-07-20 (vs Canaccord's $45 Hold a month earlier), pushing YETI through the $51.89 multi-year high. The leg still hinges on the… ZBIO Zenas BioPharma, Inc. MEDIUM First-in-disease B-cell modulator: obexelimab BLA (IgG4-RD, 56% flare cut, HR 0.44) hit the FDA 2026-05-28, and the ~60-day filing determination — acceptance plus a possible Priority Review grant — is due within days, a fresh near-term… ZETA Zeta Global Holdings Corp. MEDIUM Palantir Foundry re-platforming now has a management clock — phase one guided complete within 30–40 days of the 2026-07-06 Citi event, landing on the ~2026-08-04 Q2 print. Price reclaimed the $21 shelf that capped the June recovery (+14%… ZIP ZipRecruiter, Inc. fresh MEDIUM Q2 print on 2026-08-05 put revenue at $118.1M (+5% YoY, +10% QoQ) with Quarterly Paid Employers +12% sequentially and adjusted EBITDA margin at 12% vs 8% a year earlier, alongside a debt reduction of more than half — a trough-reversal read… ZS Zscaler, Inc. fresh MEDIUM Zscaler’s AI-security launch has renewed its recovery story, but faster growth remains unproven. Q1 FY27 revenue above the September 3 guidance of $935–939 million and a higher annual outlook would confirm the case; a weekly close below… ZYME Zymeworks Inc. fresh MEDIUM Zymeworks’ Ziihera approval supports royalty growth; Q3 2026 royalties must exceed Q2’s $1.8 million to confirm the next commercial step. A weekly close below $25 invalidates the market case before that confirmation.